Keywords: Novartis, QVA149, Seebri Breezhaler, Vectura, COPD, ERS Congress

New data from Novartis on QVA149 and Seebri Breezhaler at ERS

Article | 03 September 2012

Further data from the once-daily chronic obstructive pulmonary disease (COPD) clinical trial programs were presented yesterday by Swiss drug major ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Vectura

Go to company listing

Related Drugs

QVA149

Seebri Breezhaler

Go to drug listing